KCNK2 antibody
Principal name
KCNK2 antibody
Alternative names for KCNK2 antibody
KCNK2, TREK, TREK1, Potassium channel subfamily K member 2, Two pore potassium channel TPKC1, Outward rectifying potassium channel protein TREK-1, TREK-1 K(+) channel subunit, Two pore domain potassium channel TREK-1
Ncbi ID
NP_001017424.1, 10090, NP_055032.1, NP_034737.2, NM_001159850, NM_010607, NM_014217, NM_001017425, NM_001017424
Available reactivities
Available hosts
Available applications
Western blot / Immunoblot (WB), Enzyme Immunoassay (E)
Background of KCNK2 antibody
A potential new target for antidepressants. ture Neuroscience pp 1134-1141. A potassium channel called TREK1 may represent a new target for antidepressant drugs, according to research published in the September issue of ture Neuroscience. The channel may exert its effects through a sigling pathway in the brain different to that normally targeted by most conventiol antidepressants, which are thought to work by increasing the level of the neurotransmitter serotonin in the brain. Michel Lazdunski and colleagues studied mice lacking the gene for the TREK1 channel, which normally contributes to the background currents that set the resting membrane potential of neurons. In several behavioral tests used to model depression, these mice behaved as if they had been treated with an antidepressant. In addition, they had increased serotonergic activity, and did not release as much of the stress hormone corticosterone as normal mice in response to mild stress. Moreover, the authors report that the TREK1 channel was also directly inhibited by conventiol antidepressants. The finding that mice lacking the gene for TREK1 behave as if they have been given an antidepressant suggests that small molecule 'blockers' of the potassium channel might be effective therapeutically. If TREK1 is found to exert its antidepressant effects through a pathway independent of serotonin, it is possible that future therapies targeting TREK1 channels may be faster acting and may have fewer side effects than conventiol antidepressants. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype pp. 1134-1141. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thummler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G, Vaugeois JM, Debonnel G, Lazdunski M. Published online: 13 Aug 2006 | doi:10.1038/nn1749 TREK-1 is a two-pore-domain background potassium channel expressed throughout the central nervous system. It is opened by polyunsaturated fat


Primary Antibodies
Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
---|---|---|---|---|---|---|---|
TA301657 | KCNK2 antibody |
||||||
Rabbit Polyclonal Antibody against TREK 1 | |||||||
![]() |
Rabbit | IgG | Purified | Bov, Hu, Ms | WB |
0.1 ml /
€416.00
|
|
OriGene Technologies, Inc. | |||||||
TA318976 | KCNK2 antibody |
||||||
Rabbit polyclonal anti-Trek1 antibody | |||||||
![]() |
Rabbit | Purified | Hu, Ms, Rt | WB |
0.1 mg /
€353.00
|
||
OriGene Technologies, Inc. | |||||||
TA328611 | KCNK2 antibody |
||||||
Rabbit Polyclonal Anti-K2P2.1 (TREK-1) | |||||||
![]() |
Rabbit | Purified | Rt | WB |
0.2 ml /
€622.00
|
||
OriGene Technologies, Inc. | |||||||
AP26423AF-L | KCNK2 (4-14) antibody |
||||||
![]() |
Rabbit | Azide Free | Hu | E, WB |
0.5 mg /
€720.00
|
||
Acris Antibodies GmbH | |||||||
AP26423AF-N | KCNK2 (4-14) antibody |
||||||
![]() |
Rabbit | Azide Free | Hu | E, WB |
0.1 mg /
€340.00
|
||
Acris Antibodies GmbH | |||||||
RA25018-100 | KCNK2 (N-term) antibody |
||||||
![]() |
Rabbit | IgG | Aff - Purified | Bov, Hu, Ms | WB |
0.1 ml /
€330.00
|
|
Neuromics Antibodies |
CRISPR
Catalog No. | Species | Donor Vector | |
---|---|---|---|
KN210180 | KCNK2 - human gene knockout kit via CRISPR |
||
![]() |
Human | GFP-Puro |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN210180BN | KCNK2 - human gene knockout kit via CRISPR |
||
![]() |
Human | mBFP-Neo |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN210180LP | KCNK2 - human gene knockout kit via CRISPR |
||
![]() |
Human | Luciferase-Puro |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN210180RB | KCNK2 - human gene knockout kit via CRISPR |
||
![]() |
Human | RFP-BSD |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN308670 | Kcnk2 - mouse gene knockout kit via CRISPR |
||
![]() |
Mouse | GFP-Puro |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN308670BN | Kcnk2 - mouse gene knockout kit via CRISPR |
||
![]() |
Mouse | mBFP-Neo |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. |
Human Lenti ORF Particles
Mouse Lenti ORF Particles
Catalog No. | ||
---|---|---|
MR227299L2V | Lenti ORF particles, Kcnk2 (GFP-tagged) - Mouse potassium channel, subfamily K, member 2 (Kcnk2), transcript variant 1, 200 uL, >10^7 TU/mL |
|
![]() |
200 µl /
€907.00
|
|
OriGene Technologies, Inc. | ||
MR226715L2V | Lenti ORF particles, Kcnk2 (GFP-tagged) - Mouse potassium channel, subfamily K, member 2 (Kcnk2), transcript variant 2, 200 uL, >10^7 TU/mL |
|
![]() |
200 µl /
€907.00
|
|
OriGene Technologies, Inc. | ||